Key facts
- Santa Ana Bio’s last known valuation is $270.0M.
- It has raised $203.0M across 3 recorded rounds; the latest was Early Stage VC ($20.0M) in May 2024.
- Notable investors include Andreessen Horowitz, GV, RTW Investments, Versant Ventures, Access Biotechnology — 6 tracked in total.
- Santa Ana Bio has filed 3 Form Ds with the SEC since 2021, most recently Jun 2024 ($20.0M sold to 10 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Santa Ana Bio
Funding rounds
3 roundsAbout Santa Ana Bio
Operator of a biotechnology company intended to develop precision immunology for autoimmune diseases. The company leverages single-cell genomics and advanced analytics to design personalized biologics for autoimmune diseases, enabling patients to receive effective and targeted treatments that can lead to expected outcomes and improved quality of life.
- Sector
- Healthcare
- HQ
- Alameda, CA, United States
- Founded
- 2020
- Employees
- 38
- Website
- santaanabio.com/
- Ownership
- Privately Held (backing)
Santa Ana Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Santa Ana Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Santa Ana Bio in its N-PORT filings yet. We sweep new filings monthly.